P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000890980.06633.66 |
| _version_ | 1797287744073891840 |
|---|---|
| author | Serageldin Kamel Lucia Martiniova Eslam Aboismail Joo Schmidt Sairah Ahmed Ranjit Nair Raphael E. Steiner Michael L. Wang Sarita Soebianto Gregory Ravizzini Tinsu Pan Hun Ju Lee |
| author_facet | Serageldin Kamel Lucia Martiniova Eslam Aboismail Joo Schmidt Sairah Ahmed Ranjit Nair Raphael E. Steiner Michael L. Wang Sarita Soebianto Gregory Ravizzini Tinsu Pan Hun Ju Lee |
| author_sort | Serageldin Kamel |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:38:54Z |
| format | Article |
| id | doaj.art-070e805b624c45f8b9d902d722549360 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:38:54Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-070e805b624c45f8b9d902d7225493602024-03-02T04:19:17ZengWileyHemaSphere2572-92412022-10-016484810.1097/01.HS9.0000890980.06633.66202210005-00103P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.Serageldin Kamel0Lucia Martiniova1Eslam Aboismail2Joo Schmidt3Sairah Ahmed4Ranjit Nair5Raphael E. Steiner6Michael L. Wang7Sarita Soebianto8Gregory Ravizzini9Tinsu Pan10Hun Ju Lee111 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA2 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USA3 Department of Diagnostic Imaging-Education, The University of Texas MD Anderson Cancer Center, TX, USA4 Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, TX, USA5 Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, TX, USA1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, TX, USAhttp://journals.lww.com/10.1097/01.HS9.0000890980.06633.66 |
| spellingShingle | Serageldin Kamel Lucia Martiniova Eslam Aboismail Joo Schmidt Sairah Ahmed Ranjit Nair Raphael E. Steiner Michael L. Wang Sarita Soebianto Gregory Ravizzini Tinsu Pan Hun Ju Lee P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience. HemaSphere |
| title | P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience. |
| title_full | P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience. |
| title_fullStr | P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience. |
| title_full_unstemmed | P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience. |
| title_short | P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience. |
| title_sort | p103 comparison of pet derived parameters in program cell death 1 inhibitor and cd30 antibody drug conjugate based therapies in patients with advanced stage chl a single center experience |
| url | http://journals.lww.com/10.1097/01.HS9.0000890980.06633.66 |
| work_keys_str_mv | AT serageldinkamel p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT luciamartiniova p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT eslamaboismail p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT jooschmidt p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT sairahahmed p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT ranjitnair p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT raphaelesteiner p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT michaellwang p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT saritasoebianto p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT gregoryravizzini p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT tinsupan p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience AT hunjulee p103comparisonofpetderivedparametersinprogramcelldeath1inhibitorandcd30antibodydrugconjugatebasedtherapiesinpatientswithadvancedstagechlasinglecenterexperience |